Converge Bio raises 5.5M Seed to speed up drug discovery and development with Generative AI
CGEN Stock | USD 2.25 0.13 6.13% |
About 55% of Compugen's investors are presently thinking to get in. The analysis of overall sentiment of trading Compugen stock suggests that some investors are interested at this time. Compugen's investing sentiment overview a quick insight into current market opportunities from investing in Compugen. Many technical investors use Compugen stock news signals to limit their universe of possible portfolio assets and to time the market correctly.
Compugen |
Converge Bio, a generative AI platform for accelerated drug discovery and development, today announced it has raised 5.5 million in seed funding, led by TLV Partners. Converge Bios platform uses large language models trained on biological and chemical data to help biotech and pharmaceutical companies discover and develop better-performing drugs in less time.
Read at finance.yahoo.com
Compugen Fundamental Analysis
We analyze Compugen's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Compugen using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Compugen based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Price To Sales
Price To Sales Comparative Analysis
Compugen is currently under evaluation in price to sales category among its peers. Price to Sales ratio is typically used for valuing equity relative to its own past performance as well as to performance of other companies or market indexes. In most cases, the lower the ratio, the better it is for investors. However, it is advisable for investors to exercise caution when looking at price-to-sales ratios across different industries.
Compugen Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Compugen stock to make a market-neutral strategy. Peer analysis of Compugen could also be used in its relative valuation, which is a method of valuing Compugen by comparing valuation metrics with similar companies.
Peers
Compugen Related Equities
EVGN | Evogene | 10.56 | ||||
ICCC | ImmuCell | 5.16 | ||||
ITOS | Iteos Therapeutics | 3.36 | ||||
ANNX | Annexon | 2.19 | ||||
PHGE | Biomx | 1.32 | ||||
CLGN | Collplant Biotechnologies | 0.50 | ||||
BEAM | Beam Therapeutics | 0.17 | ||||
CRBU | Caribou Biosciences | 0.65 | ||||
ALLO | Allogene Therapeutics | 1.09 | ||||
EDIT | Editas Medicine | 1.61 | ||||
PLUR | Pluri | 2.48 | ||||
CANF | Can Fite | 2.52 | ||||
SANA | Sana Biotechnology | 2.77 |
Check out Compugen Hype Analysis, Compugen Correlation and Compugen Performance. To learn how to invest in Compugen Stock, please use our How to Invest in Compugen guide.You can also try the Investing Opportunities module to build portfolios using our predefined set of ideas and optimize them against your investing preferences.
Is Life Sciences Tools & Services space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Compugen. If investors know Compugen will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Compugen listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Compugen is measured differently than its book value, which is the value of Compugen that is recorded on the company's balance sheet. Investors also form their own opinion of Compugen's value that differs from its market value or its book value, called intrinsic value, which is Compugen's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Compugen's market value can be influenced by many factors that don't directly affect Compugen's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Compugen's value and its price as these two are different measures arrived at by different means. Investors typically determine if Compugen is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Compugen's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.